$A

Dolsten Mikael sold $217K of A

Dolsten Mikael sold 1,600 shares of AGILENT TECHNOLOGIES, INC. (A) at $135.42 ($0.22M total) on 2026-05-29.

Original reporting
SEC EDGAR · Dolsten Mikael
Published Jun 2, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$A
Neutral
medium confidence
Mentioned
$A
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity, but this filing alone does not change the company’s fundamentals.

02

Market read

A director’s open-market sale is disclosed; absent other catalysts, expected impact is modest.

03

What to watch

No 10b5-1 plan is cited, but the sale size ($216.7K) is small relative to typical large-cap float, reducing interpretive power.

Relevance 6/10Novelty 6/10Timing: today’s SEC Form 4 disclosure (filed 2026-06-02)

Background

The article is an SEC EDGAR Form 4 insider transaction: a director reports an open-market sale of Agilent shares.

Company-level read

Ticker impact

$ANeutralMedium confidence
Context

Agilent director Dolsten Mikael sold 1,600 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; treat as low-signal unless part of a broader selling pattern.

Evidence & confidence

This is a routine Form 4 sale with no 10b5-1 plan and no accompanying fundamental news, so market reaction is typically muted.

Market effects

Minimal; this is company-specific insider activity with no sector-wide read-across.

None indicated.

None indicated.

Counterpoint

A single director sale can reflect diversification or liquidity needs rather than bearish fundamentals.

Key entities

  • Agilent Technologies, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • Dolsten Mikael

    Director who sold 1,600 shares at $135.42 on 2026-05-29.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMed

Agilent (A) Upgraded to Buy: What Does It Mean for the Stock?

Agilent Technologies (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks rating system, which is based on earnings estimate revisions, suggests a positive outlook for the company's stock price. Analysts have raised their estimates for Agilent by 3.4% over the past three months, with the company expected to earn $6.17 per share for the fiscal year ending October 2026.

$AHighAI 8/10

Agilent (A) Q3 2026 Earnings Call Transcript

Agilent (A) reported Q3 2026 revenue of $1.88B, up 7.3% and exceeding guidance. EPS was $1.56, up 14% YoY. Strong performance driven by pharma, China growth, and Ignite strategy. Key growth areas include pharma, semiconductors, and AI infrastructure.

$AHighAI 8/10

Stronger Q3 Results and Raised Guidance Could Be A Game Changer For Agilent Technologies (A)

Agilent Technologies (A) reported Q3 2026 sales of $1.88B and net income of $362M, with EPS rising to $1.28. The company raised its full-year revenue and profit guidance, citing strong demand in pharma, China, and advanced materials, plus cost savings from its Ignite program. The updated outlook suggests margin benefits and product launches are offsetting cost pressures. Investors should note ongoing tariff and supply chain risks. Analysts' fair value estimates for Agilent range from $150.54 to

$AHighAI 8/10

Agilent earnings analysis: questions answered and next catalysts

Agilent reported FY2026 Q3 earnings with EPS of $1.62 (8.7% above consensus) and revenue of $1.88B (2.2% above estimates). This marks the third consecutive quarter of EPS acceleration, with revenue growth of 6.7% in FY2025. However, gross margins slipped to 52.4% and free cash flow declined to $1.15B. The stock trades at 30.9x trailing P/E, with a fair-value estimate of $145.64, suggesting a 7.6% overvaluation.